9.3 Online Preliminary

 Participants

Replication Medical Inc.

Replication Medical develops and manufactures a broad portfolio of implantable medical devices based on its proprietary hydrogel platform technology,especially unique products that mimic or “replicate” the bodies natural tissues.

Healium Medical

Healium Medical is developing advanced ultrasound-based technology for atrial fibrillation, the most common cardiac arrhythmia affecting millions worldwide and a leading cause of stroke, which is a large and growing market space with very large potential in China.

Our proprietary ultrasound technology allows no-contact treatment using acoustic energy + real-time monitoring with a single catheter.  This is in sharp contrast to all existing solutions that require contact and offer no real-time monitoring.

The atrial fibrillation is large and growing market exceeding > $3.5B/year in sales with vibrant M&A activity, ~$1B past 12months, but poor 60% clinical efficacy due to limitations of existing technologies.

 

Microvascular Therapeutics, LLC

Healium Medical is developing advanced ultrasound-based technology for atrial fibrillation, the most common cardiac arrhythmia affecting millions worldwide and a leading cause of stroke, which is a large and growing market space with very large potential in China.

Our proprietary ultrasound technology allows no-contact treatment using acoustic energy + real-time monitoring with a single catheter.  This is in sharp contrast to all existing solutions that require contact and offer no real-time monitoring.

 

iNNOGING Medical

iNNOGING will solve the bottleneck – radiologists can remotely navigate in exams taken by tech’s without being next to the patient and see important elements in those exams that the technician recorded but hasn’t provided. We reconstruct the 2D info received from the U/S machine and create 3D representation to navigate in.

We reconstruct the 2D info received from the U/S machine and create 3D representation to navigate in!

We allow navigating in Ultrasound exams as if the patient was near the radiologist. With our technology we extract video frames from a DICOM file, then position each frame one after the other just like slices in a CT scan, in order to create a 3D volumetric representation. This allows us to dynamically extract new slices, that were not shown in the original video.

SynergyMed Ltd

SynergyMed Ltd. (“SynergyMed”) is a medical device company developing a non-invasive electromagnetic ablation systems for the treatment of cancerous tumors as an alternative to surgery.

SynergyMed proven technology overcomes these clinical and operating limitations, enabling pain-free, non-invasive ablation of tumors, through thermal ablation which provides an effective intervention for multiple types of cancer. The company has identified a number of cancers, including non-metastasized breast cancer, head and neck cancer, lung, melanoma and glioblastoma, where its platform technology offers either a first-line treatment option or an adjuvant treatment to surgery, radiation or chemotherapy. The treatment can be safely performed in outpatient settings, including hospital-based and free-standing clinics.

 

Encendia Therapeutics Inc.

– Focused on technology that aims to disrupt the current dogma associated with fatty liver disease (NAFLD) and NASH, we are addressing the imbalance between energy storage (fat) and energy expenditure triggered by low-grade inflammation that is a consequence of obesity.  The signaling pathway involved in this mechanism (IKKe/TBK1) activates the non-apoptotic caspase, caspase 2 that is responsible for uncontrolled de novo lipid and cholesterol synthesis that is never counter-balanced, leading to fat deposition in the liver, cell death and pro-fibrotic signaling. 

 – Targets are validated by significant pre-clinical and clinical data (an approved drug used as a tool for early p.o.c.).  The pre-approved drug can feasibly enter a 505(b)(2) regulatory assessment if we can perform further formulation work and develop the pre-clinical program.  Early PhI data with this drug suggests an efficacious response in NASH.

 – The management team has a strong track record in industry (pharma and biotech), having progressed multiple NCE candidates to the clinic.

  Judges

Hui Wang, MD

Manager

WEGO HOLDING COMPANY LIMITED (“WEGO”)

Dou Dou

Investment Manager

Oriza Seed Fund Management

Maggie Wang

Business Development Manager

Button Capital

Kaixuan Liu

Investment Director-Healthcare

Cybernaut(China) Investment

Stone Zhang, PhD

Managing Director

InnovationMap Inc

Yun Qin, PhD

Investment Director

ZhuHai Institute of Advanced Technology Chinese Acadamy of Science